Literature DB >> 9613707

Lactoferrin lowers serum interleukin 6 and tumor necrosis factor alpha levels in mice subjected to surgery.

M Zimecki1, A Właszczyk, T Zagulski, A Kübler.   

Abstract

Mice subjected to thymectomy or splenectomy in general anesthesia release interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) into circulation reaching high concentrations after 4 h following operation. In the case of thymectomy IL-6 can be detected only on the day of operation and TNF-alpha attains a maximal value on day 3 postoperation. Splenectomy, which is a more extensive surgical operation, results in a higher, and more prolonged existence of IL-6 in circulation accompanied by higher levels of TNF-alpha. Bovine lactoferrin (BLF; 10 mg/mouse), given intravenously (i.v.) 24 h before thymectomy, reduced, on average, the level of serum IL-6 by 70% as measured 4 h after operation. The inhibiting effect of BLF on TNF-alpha production was smaller with a mean 30% reduction. The effects of BLF (i.v.) administration on the cytokine levels following splenectomy were less inhibitory. BLF caused an approximate 35% fall in IL-6 levels and even weaker effects (20% inhibition) on TNF-alpha release. Application of much lower (1-0.2 mg) per os doses of BLF was even more effective in lowering IL-6 levels after thymectomy (up to 90%) after 5 BLF doses, and by 55% of TNF-alpha. The data suggest that lactoferrin may find therapeutical application for diminishing manifestations of shock caused by clinical insults.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9613707

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  8 in total

1.  Lactoferrin decreases pollen antigen-induced allergic airway inflammation in a murine model of asthma.

Authors:  Marian L Kruzel; Attila Bacsi; Barun Choudhury; Sanjiv Sur; Istvan Boldogh
Journal:  Immunology       Date:  2006-06-26       Impact factor: 7.397

Review 2.  Inflammation: a highly conserved, Janus-like phenomenon-a gastroenterologist' perspective.

Authors:  Davide Giuseppe Ribaldone; Rinaldo Pellicano; Giovanni Clemente Actis
Journal:  J Mol Med (Berl)       Date:  2018-07-09       Impact factor: 4.599

Review 3.  Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer's Disease Patients.

Authors:  Fernando Bartolomé; Luigi Rosa; Piera Valenti; Francisco Lopera; Jesús Hernández-Gallego; José Luis Cantero; Gorka Orive; Eva Carro
Journal:  Front Immunol       Date:  2022-04-25       Impact factor: 8.786

4.  Human lactoferrin induces asthmatic symptoms in NC/Nga mice.

Authors:  Kenjiro Nagaoka; Tatsuo Ito; Keiki Ogino; Eri Eguchi; Yoshihisa Fujikura
Journal:  Physiol Rep       Date:  2017-08

Review 5.  Lactoferrin in a Context of Inflammation-Induced Pathology.

Authors:  Marian L Kruzel; Michal Zimecki; Jeffrey K Actor
Journal:  Front Immunol       Date:  2017-11-06       Impact factor: 7.561

6.  Lactoferrin Ameliorates Dry Eye Disease Potentially through Enhancement of Short-Chain Fatty Acid Production by Gut Microbiota in Mice.

Authors:  Samuel Connell; Motoko Kawashima; Shigeru Nakamura; Toshihiro Imada; Hiromitsu Yamamoto; Kazuo Tsubota; Shinji Fukuda
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 5.923

Review 7.  Immunomodulation to Prevent or Treat Neonatal Sepsis: Past, Present, and Future.

Authors:  Simone S Schüller; Boris W Kramer; Eduardo Villamor; Andreas Spittler; Angelika Berger; Ofer Levy
Journal:  Front Pediatr       Date:  2018-07-19       Impact factor: 3.418

8.  Impact of lactoferrin on bone regenerative processes and its possible implementation in oral surgery - a systematic review of novel studies with metanalysis and metaregression.

Authors:  Grzegorz Trybek; Maciej Jedliński; Aleksandra Jaroń; Olga Preuss; Marta Mazur; Anna Grzywacz
Journal:  BMC Oral Health       Date:  2020-08-26       Impact factor: 2.757

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.